$LFVN
Lifevantage Corp Stock $lfvn

$lfvn Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000084914617000081 Filed on May 10, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$50.64M	$45.01M	$56.16M
YoY Change	-4.51%	-19.86%	24.37%
Cost Of Revenue	$8.890M	$8.233M	$9.714M
YoY Change	-5.43%	-15.25%	28.63%
Gross Profit	$41.75M	$36.77M	$46.45M
YoY Change	-4.31%	-20.82%	23.52%
Gross Profit Margin	82.44%	81.71%	82.7%
Selling, General & Admin	$40.21M	$13.71M	$14.63M
YoY Change	1.67%	-6.3%	1.03%
% of Gross Profit	96.31%	37.28%	31.5%
Research & Development		$200.0K
YoY Change
% of Gross Profit		0.54%
Depreciation & Amortization	$420.0K	$390.0K	$440.0K
YoY Change	-12.5%	-11.36%	-22.81%
% of Gross Profit	1.01%	1.06%	0.95%
Operating Expenses	$40.21M	$36.55M	$42.82M
YoY Change	1.67%	-14.63%	18.54%
Operating Profit	$1.540M	$223.0K	$3.631M
YoY Change	-62.27%	-93.86%	144.51%
Interest Expense	-$250.0K	$131.0K	$1.808M
YoY Change	-725.0%	-92.75%	141.71%
% of Operating Profit	-16.23%	58.74%	49.79%
Other Income/Expense, Net	-$530.0K	-$163.0K	-$1.854M
YoY Change	-60.45%	-91.21%	143.63%
Pretax Income	$760.0K	$60.00K	$1.777M
YoY Change	-72.66%	-96.62%	145.44%
Income Tax	$680.0K	-$1.000K	$774.0K
% Of Pretax Income	89.47%	-1.67%	43.56%
Net Earnings	$84.00K	$61.00K	$1.003M
YoY Change	-96.55%	-93.92%	75.04%
Net Earnings / Revenue	0.17%	0.14%	1.79%
Basic Earnings Per Share	$0.01	$0.00	$0.07
Diluted Earnings Per Share	$0.01	$0.00	$0.07
COMMON SHARES
Basic Shares Outstanding	14.23M shares	13.92M shares	13.73M shares
Diluted Shares Outstanding		14.11M shares	14.13M shares

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.46M	$9.200M	$8.490M
YoY Change	45.43%	8.36%	-44.69%
Cash & Equivalents	$11.46M	$9.202M	$8.494M
Short-Term Investments
Other Short-Term Assets	$5.270M	$5.720M	$5.950M
YoY Change	-38.43%	-3.87%	54.15%
Inventory	$16.58M	$19.15M	$17.00M
Prepaid Expenses
Receivables	$1.334M	$1.151M	$2.042M
Other Receivables	$920.0K	$2.630M	$2.230M
Total Short-Term Assets	$35.55M	$37.85M	$35.71M
YoY Change	-17.55%	6.0%	2.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.127M	$2.878M	$4.981M
YoY Change	-9.52%	-42.22%	-20.16%
Goodwill
YoY Change
Intangibles	$1.247M	$1.665M	$1.778M
YoY Change	-28.5%	-6.36%	-7.06%
Long-Term Investments
YoY Change
Other Assets	$1.242M	$1.335M	$1.427M
YoY Change	-18.29%	-6.45%	-2.79%
Total Long-Term Assets	$9.703M	$8.896M	$8.415M
YoY Change	25.31%	5.72%	-30.28%
TOTAL ASSETS
Total Short-Term Assets	$35.55M	$37.85M	$35.71M
Total Long-Term Assets	$9.703M	$8.896M	$8.415M
Total Assets	$45.25M	$46.74M	$44.12M
YoY Change	-11.02%	5.95%	-5.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.850M	$6.493M	$5.938M
YoY Change	-45.45%	9.35%	118.07%
Accrued Expenses	$16.29M	$16.42M	$17.36M
YoY Change	-0.97%	-5.41%	34.89%
Deferred Revenue	$1.743M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.000M	$2.000M	$2.000M
YoY Change	0.0%	0.0%	-78.26%
Total Short-Term Liabilities	$23.36M	$24.91M	$25.30M
YoY Change	-23.75%	-1.52%	2.02%
LONG-TERM LIABILITIES
Long-Term Debt	$5.440M	$5.932M	$7.901M
YoY Change	-26.58%	-24.92%	-54.05%
Other Long-Term Liabilities	$1.927M	$2.005M	$2.084M
YoY Change	-11.16%	-3.79%	-1.0%
Total Long-Term Liabilities	$7.367M	$7.937M	$9.985M
YoY Change	-23.08%	-20.51%	-48.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.36M	$24.91M	$25.30M
Total Long-Term Liabilities	$7.367M	$7.937M	$9.985M
Total Liabilities	$30.72M	$32.85M	$35.28M
YoY Change	-23.59%	-6.9%	-19.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$107.0M	-$106.6M	-$110.4M
YoY Change	-1.48%	-3.51%	-3.41%
Common Stock	$121.6M	$120.5M	$119.4M
YoY Change	1.98%	0.91%	1.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.53M	$13.90M	$8.839M
YoY Change
Total Liabilities & Shareholders Equity	$45.25M	$46.74M	$44.12M
YoY Change	-11.02%	5.95%	-5.98%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	$84.00K	$61.00K	$1.003M
YoY Change	-96.55%	-93.92%	75.04%
Depreciation, Depletion And Amortization	$420.0K	$390.0K	$440.0K
YoY Change	-12.5%	-11.36%	-22.81%
Cash From Operating Activities	$1.980M	-$480.0K	-$2.310M
YoY Change	-1337.5%	-79.22%	-333.33%
INVESTING ACTIVITIES
Capital Expenditures	-$600.0K	-$220.0K	-$170.0K
YoY Change	900.0%	29.41%	-29.17%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$600.0K	-$220.0K	-$170.0K
YoY Change	900.0%	29.41%	-29.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	880.0K	-1.850M	-4.940M
YoY Change	-300.0%	-62.55%	22.28%
NET CHANGE
Cash From Operating Activities	1.980M	-480.0K	-2.310M
Cash From Investing Activities	-600.0K	-220.0K	-170.0K
Cash From Financing Activities	880.0K	-1.850M	-4.940M
Net Change In Cash	2.260M	-2.550M	-7.420M
YoY Change	-442.42%	-65.63%	125.53%
FREE CASH FLOW
Cash From Operating Activities	$1.980M	-$480.0K	-$2.310M
Capital Expenditures	-$600.0K	-$220.0K	-$170.0K
Free Cash Flow	$2.580M	-$260.0K	-$2.140M
YoY Change	-2680.0%	-87.85%	-273.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000849146
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14232609	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Lifevantage Corp
	dei	Trading Symbol TradingSymbol	LFVN
CY2016Q1	lfvn	Commission And Incentives CommissionAndIncentives	28185000	USD
	lfvn	Commission And Incentives CommissionAndIncentives	77525000	USD
CY2017Q1	lfvn	Commission And Incentives CommissionAndIncentives	22843000	USD
	lfvn	Commission And Incentives CommissionAndIncentives	72679000	USD
	lfvn	Money Back Guarantee Period MoneyBackGuaranteePeriod	P30D
	lfvn	Number Of Geographic Segments NumberOfGeographicSegments	2	Segment
CY2017Q1	lfvn	Percent Of Restocking Fee PercentOfRestockingFee	0.1
CY2016Q2	lfvn	Reserve For Sales Returns ReserveForSalesReturns	300000	USD
CY2017Q1	lfvn	Reserve For Sales Returns ReserveForSalesReturns	500000	USD
CY2017Q1	lfvn	Revenue Recognition Sale Returns Acceptable Percentage From Terminated Distributors RevenueRecognitionSaleReturnsAcceptablePercentageFromTerminatedDistributors	0.3
CY2017Q1	lfvn	Sharebased Compensation Arrangementby Sharebased Payment Award Increase Decreaseof Sharebased Liabilities SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseDecreaseofSharebasedLiabilities	12000	USD
	lfvn	Sharebased Compensation Arrangementby Sharebased Payment Award Increase Decreaseof Sharebased Liabilities SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseDecreaseofSharebasedLiabilities	200000	USD
	lfvn	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	-1341000	USD
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	8891000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6493000	USD
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1552000	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1151000	USD
CY2016Q2	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	7719000	USD
CY2017Q1	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	6851000	USD
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	43000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-29000	USD
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	120150000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	120462000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	700000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1200000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	600000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1700000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1653000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	178000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	14000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	229000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	9000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	100000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	200000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	281000	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	200000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	100000	shares
CY2016Q2	us-gaap	Assets Assets	50259000	USD
CY2017Q1	us-gaap	Assets Assets	46743000	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	42409000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	37847000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13905000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8494000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7883000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9202000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5411000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1319000	USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14028000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14232000	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14028000	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14232000	shares
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	14000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	14000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1105000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3797000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	87000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1452000	USD
CY2016Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9714000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	24531000	USD
CY2017Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8233000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	24565000	USD
CY2016Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	7500000	USD
CY2017Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	6000000	USD
CY2016Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	91000	USD
CY2017Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	68000	USD
CY2017Q1	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	8000000	USD
CY2017Q1	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	100000	USD
CY2017Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	3018000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	37000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	888000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	2776000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	1130000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1424000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1224000	USD
CY2016Q1	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-200000	USD
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-200000	USD
CY2017Q1	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-200000	USD
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-100000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.26
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.11
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	145000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2000	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.291
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	361000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	-1380000	USD
CY2016Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	200000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-22000	USD
CY2017Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	200000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-200000	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	46446000	USD
	us-gaap	Gross Profit GrossProfit	128976000	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	36774000	USD
	us-gaap	Gross Profit GrossProfit	124283000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1777000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	5902000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	60000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2150000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	774000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2200000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2233000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	600000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	626000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1373000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	4455000	USD
CY2016Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
CY2017Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	2631000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	737000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4561000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1006000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2287000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3955000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-796000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7683000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-5724000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-250000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-90000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	717000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-564000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-570000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1564000	USD
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	73000	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	70000	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	321000	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	190000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	264000	shares
CY2016Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1744000	USD
CY2017Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1665000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	1808000	USD
	us-gaap	Interest Expense InterestExpense	3176000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	131000	USD
	us-gaap	Interest Expense InterestExpense	406000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	24000	USD
	us-gaap	Interest Paid InterestPaid	1216000	USD
	us-gaap	Interest Paid InterestPaid	338000	USD
CY2016Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	14852000	USD
CY2017Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	9459000	USD
CY2016Q2	us-gaap	Inventory Net InventoryNet	25116000	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	19145000	USD
CY2016Q2	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	10264000	USD
CY2017Q1	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	9686000	USD
CY2016Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	400000	USD
CY2017Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	800000	USD
CY2016Q2	us-gaap	Liabilities Liabilities	38128000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	32848000	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50259000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	46743000	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	28550000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	24911000	USD
CY2016Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2000000	USD
CY2017Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	2000000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	5500000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2000000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	500000	USD
CY2016Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7409000	USD
CY2017Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5932000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11255000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2840000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-499000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-464000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6198000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4621000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	1003000	USD
	us-gaap	Net Income Loss NetIncomeLoss	3669000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	61000	USD
	us-gaap	Net Income Loss NetIncomeLoss	1524000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	116000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1854000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3432000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-163000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-759000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	42815000	USD
	us-gaap	Operating Expenses OperatingExpenses	119642000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	36551000	USD
	us-gaap	Operating Expenses OperatingExpenses	121374000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3631000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	9334000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	223000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	2909000	USD
CY2016Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8734000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9567000	USD
CY2016Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1520000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1335000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	102000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	128000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	26000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-72000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	102000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	128000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	26000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-72000	USD
CY2016Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2169000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2005000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-46000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-256000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-32000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-353000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	99000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	499000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	464000	USD
CY2016Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2016Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5082000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5718000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	108000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	40000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	10000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3456000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2878000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	21625000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1500000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	700000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	800000	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-108076000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-106552000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	56160000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	153507000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	45007000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	148848000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1577000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14630000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	42117000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13708000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	48695000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	1125000	shares
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	12131000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	13895000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1792000	USD
CY2015Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1429
CY2016Q2	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	1206000	USD
CY2017Q1	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	0	USD
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14128000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14072000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14105000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14122000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13734000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13721000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13915000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13858000	shares
	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	1544000	USD
	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	0	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounting guidance for financial instruments requires disclosure of significant concentrations of credit risk regardless of the degree of such risk. Financial instruments with significant credit risk include cash and investments.</font></div></div>
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for contingent liabilities in accordance with Accounting Standards Codification ("ASC") Topic 450, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies</font><font style="font-family:inherit;font-size:10pt;">. This guidance requires management to assess potential contingent liabilities that may exist as of the date of the financial statements to determine the probability and amount of loss that may have occurred, which inherently involves an exercise of judgment. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. For loss contingencies considered remote, no accrual or disclosures are generally made. Management has assessed potential contingent liabilities as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, and based on the assessment there are no probable loss contingencies requiring accrual or disclosures within these financial statements and footnotes.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Legal Accruals</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to commitments and obligations in the ordinary course of business, from time to time, the Company is subject to various claims, pending and potential legal actions, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of our business. Management assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in our consolidated financial statements. An estimated loss contingency is accrued in our consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because evaluating legal claims and litigation results are inherently unpredictable and unfavorable results could occur, assessing contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, management may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed or asserted against the Company may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of a potential liability. Management regularly reviews contingencies to determine the adequacy of financial statement accruals and related disclosures. The amount of ultimate loss may differ from these estimates. It is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one or more of these contingencies. Whether any losses finally determined in any claim, action, investigation or proceeding could reasonably have a material effect on the Company's business, financial condition, results of operations or cash flows will depend on a number of variables, including: the timing and amount of such losses; the structure and type of any remedies; the significance of the impact any such losses, damages or remedies may have on our consolidated financial statements; and the unique facts and circumstances of the particular matter that may give rise to additional factors. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Former Distributor Lawsuit:</font><font style="font-family:inherit;font-size:10pt;"> On November 20, 2013, the Company filed a complaint in the United States District Court, District of Utah, Central Division naming Jason Domingo and Ovation Marketing Group, Inc. as defendants. Ovation Marketing Group, Inc. is a former distributor of the company. In the complaint, the Company alleges that the defendants breached a contract and misappropriated the Company's trade secrets. On January 21, 2014, the defendants filed an answer and counterclaim in response to the complaint. The defendants' answer and counterclaims allege defamation and tortious interference with economic relations, which the defendants claim resulted in damages of not less than </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;">. On December 14, 2015, the Company filed a motion for summary judgment seeking judgment in its favor on the Company's breach of contract claim and dismissal of all defendants’ counterclaims. Also on December 14, 2015, defendants filed a motion for summary judgment seeking dismissal of the Company's claim for misappropriation of trade secrets and to dismiss the Company's judicial proceedings privilege defense against the defamation claim. The Court heard oral argument on the motions for summary judgment on May 17, 2016. The court granted summary judgment in favor of the Company on its breach of contract claims and dismissed the Company's trade secret claim for lack of proof of damages. Subsequently, on February 10, 2017, the Company entered into a confidential settlement agreement with the defendants and all claims and counter claims have now been dismissed with prejudice.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Class Action Lawsuit: </font><font style="font-family:inherit;font-size:10pt;"> On September 15, 2016, a purported securities class action was filed in the United States District Court for the District of Utah, entitled Zhang v. LifeVantage Corp., Case No. 2:16-cv-00965-BCW (D. Utah filed Sept. 15, 2016).  In this action (now recaptioned as In re LifeVantage Corp. Securities Litigation), plaintiff alleges that the Company, its Chief Executive Officer and now-former Chief Financial Officer violated Sections 10(b) and/or 20(a) of the Securities Exchange Act of 1934, 15 U.S.C. §§ 78j(b), 78t(a), and Rule 10b-5, 17 C.F.R. § 240.10b-5, promulgated thereunder, by making false or misleading statements or omissions in public filings with the Securities and Exchange Commission regarding the Company's internal controls and financial results for the first, second and third quarters of fiscal year 2016.  The initial complaint sought unspecified damages against the defendants on behalf of a class of purchasers of the Company’s stock between November 4, 2015 and September 13, 2016.  By stipulation filed October 7, 2016, the parties agreed that defendants need not respond to the initial complaint in the action until after a lead plaintiff is appointed pursuant to the Private Securities Litigation Reform Act of 1995 (“PSLRA”), at which time the parties will meet and confer regarding the timing of the filing of an amended complaint and responses thereto.  On November 14, 2016, three motions for appointment as lead plaintiff were filed.  On December 13, 2016, the Court appointed Dale Blanch and Yvonne Cohen as lead plaintiffs and approved their selection of lead plaintiffs’ counsel.  On January 27, 2017, lead plaintiffs filed an amended complaint.  On March 13, 2017, defendants filed a motion to dismiss the amended complaint for failure to state a claim for relief and a motion to strike certain irrelevant matters from the amended complaint.  Lead plaintiffs filed their opposition to defendants’ motions on April 19, 2017.  Defendants filed their reply on May 10, 2017.  The Court has not set a hearing date for the motion.  By operation of the PSLRA, all discovery and other proceedings are stayed in this action pending a ruling on defendants’ motion to dismiss.  The Company has not established a loss contingency accrual for this lawsuit as it believes liability is not probable or estimable, and the Company plans to vigorously defend against this lawsuit. Nonetheless, an unfavorable resolution of this matter could have a material adverse effect on the Company's business, results of operations or financial condition.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative Action Lawsuits:</font><font style="font-family:inherit;font-size:10pt;"> On October 11, 2016, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:11pt;"> </font><font style="font-family:inherit;font-size:10pt;">purported shareholder derivative actions were filed in the Third District Court of the State of Utah, Salt Lake County, entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Johnson v. Jensen</font><font style="font-family:inherit;font-size:10pt;">, Case No. 160906320 MI (Utah Dist. filed Oct. 11, 2016), and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rupp v. Jensen</font><font style="font-family:inherit;font-size:10pt;">, Case No. 160906321 MI (Utah Dist. filed Oct. 11, 2016).  In these actions (which are substantively identical), plaintiffs, purportedly on behalf of the Company, allege that the Company's Chief Executive Officer, now-former Chief Financial Officer and members of the Board of Directors breached their fiduciary duties owed to the Company by, among other things, causing or permitting the Company to issue false and misleading statements or omissions in public filings with the Securities and Exchange Commission, as alleged in the class action lawsuit noted above.  On October 19, 2016, the Court entered an order consolidating the two actions under the Johnson case number, with the new caption </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">In re LifeVantage Corp. Derivative Litigation</font><font style="font-family:inherit;font-size:10pt;">, providing that defendants and nominal defendant need not respond to the initial complaints and directing the parties to meet and confer within thirty days on a schedule for further proceedings in this action.  On November 21, 2016, the Court approved a stipulation between the parties providing that (a) defendants and nominal defendant need not respond to the initial complaints and (b) within thirty days from the earlier of (i) the Company’s filing of its Form 10-K for fiscal year 2016 and (ii) plaintiffs’ filing of a consolidated amended complaint, the parties will meet and confer on a schedule regarding further proceedings in this action.  On January 10, 2017, the Court approved a stipulation between the parties providing that this action would be deferred (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:inherit;font-size:10pt;">, stayed) pending a ruling on defendants’ then-anticipated motion to dismiss the amended complaint in the Class Action Lawsuit.  On March 13, 2017, plaintiffs filed a consolidated amended complaint.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 30, 2017, another purported shareholder derivative action was filed in the United States District Court for the District of Utah, entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hansen v. Jensen</font><font style="font-family:inherit;font-size:10pt;">, Case No. 2:17-cv-00075-DN (D. Utah filed Jan. 30, 2017).  In this action, plaintiff, purportedly on behalf of the Company, alleges that the Company’s Chief Executive Officer, now-former Chief Financial Officer and members of the Board of Directors violated Section 14(a) of the Securities Exchange Act of 1934, 15 U.S.C. § 78n(a), and breached their fiduciary duties owed to the Com-pany by, among other things, causing or permitting the Company to issue false and misleading statements or omissions in public filings with the SEC, as alleged in the class action lawsuit noted above.  On March 30, 2017, the parties entered into a stipulation providing that this action would be stayed pending a ruling on defendants’ motion to dismiss the amended complaint in the Class Action Lawsuit.  On February 27, 2017, another purported shareholder derivative action was filed in the United States District Court for the District of Utah, entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Baker v. Jensen</font><font style="font-family:inherit;font-size:10pt;">, Case No. 2:17-cv-00141-PMW (D. Utah filed Feb. 27, 2017).  Also, on April 24, 2017, another purported shareholder derivative action was filed in the United States District Court for the District of Utah, entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inforzato v. Jensen</font><font style="font-family:inherit;font-size:10pt;">, Case No. 2:17-cv-00317-JNP (D. Utah filed Apr. 24, 2017).  In these actions, plaintiffs, also purportedly on behalf of the Company, make similar allegations as the plaintiff in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hansen v. Jensen</font><font style="font-family:inherit;font-size:10pt;">, described above.  The deadline for defendants and nominal defendant to respond to the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Baker</font><font style="font-family:inherit;font-size:10pt;"> complaint is June 12, 2017.  The </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inforzato</font><font style="font-family:inherit;font-size:10pt;"> complaint has not yet been served.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company notes that although the plaintiffs in the Derivative Action Lawsuits purport to seek unspecified damages against the individual defendants on behalf of the Company, the Company owes certain indemnification obligations to these individual defendants under Colorado law and existing indemnification agreements.  The Company has not established a loss contingency accrual for this lawsuit as it believes liability is not probable or estimable, and the defendants plan to vigorously defend against this lawsuit.  Nonetheless, an unfavorable resolution of this matter could have a material adverse effect on the Company's business, results of operations or financial condition.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Matters.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">In addition to the matters described above, the Company also may become involved in other litigation and regulatory matters incidental to its business and the matters disclosed in this Quarterly Report on Form 10-Q, including, but not limited to, product liability claims, regulatory actions, employment matters and commercial disputes. The Company intends to defend itself in any such matters and does not currently believe that the outcome of any such matters will have a material adverse effect on the Company's business, financial condition, results of operations and cash flows.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We prepare our consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America (GAAP). In preparing these statements, we are required to use estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates and assumptions. On an ongoing basis, we review our estimates, including those related to inventory valuation and obsolescence, sales returns, income taxes and tax valuation reserves, share-based compensation, and loss contingencies.</font></div></div>

Files In Submission

Name	View Source	Status
0000849146-17-000081-index-headers.html	Edgar Link	pending
0000849146-17-000081-index.html	Edgar Link	pending
0000849146-17-000081.txt	Edgar Link	pending
0000849146-17-000081-xbrl.zip	Edgar Link	pending
a101markjaggiseparationagr.htm	Edgar Link	pending
a105stevefifeofferletter.htm	Edgar Link	pending
a106executivebenefits-fife.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lfvn-20170331.xml	Edgar Link	completed
lfvn-20170331.xsd	Edgar Link	pending
lfvn-20170331_cal.xml	Edgar Link	unprocessable
lfvn-20170331_def.xml	Edgar Link	unprocessable
lfvn-20170331_lab.xml	Edgar Link	unprocessable
lfvn-20170331_pre.xml	Edgar Link	unprocessable
lfvn_33117x10q.htm	Edgar Link	pending
lfvn_33117xex311.htm	Edgar Link	pending
lfvn_33117xex312.htm	Edgar Link	pending
lfvn_33117xex321.htm	Edgar Link	pending
lfvn_33117xex322.htm	Edgar Link	pending
logoa06.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LFVN
Lifevantage Corp Stock $lfvn

2017 Q2 Form 10-Q Financial Statement

#000084914617000081 Filed on May 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LFVN Lifevantage Corp Stock $lfvn

2017 Q2 Form 10-Q Financial Statement

#000084914617000081 Filed on May 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LFVN
Lifevantage Corp Stock $lfvn